



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE
STATE HAVING A MOLECULAR WEIGHT OF
1518 DALTONS
SERIAL NUMBER : 09/845,765
FILING DATE : 04/30/01
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1616
ATTORNEY DOCKET NO. : 2132.036

RECEIVED
DEC 17 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 12/9/03

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.


Date:

12/9/2002

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



RECEIVED
DEC 17 2002 #4
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE
STATE HAVING A MOLECULAR WEIGHT OF
1518 DALTONS
SERIAL NUMBER : 09/845,765
FILING DATE : 04/30/01
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1616
ATTORNEY DOCKET NO. : 2132.036

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 12-9-02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:


- X Supplemental Information Disclosure Statement
- X Certification Pursuant to 37 C.F.R. §1.97(e)
- X Copy of International Search Report
- X PTO-1449
- X References

Respectfully Submitted,

Date: 12/9/2002

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
DEC 17 2002
TECH CENTER 1689/2900

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE
STATE HAVING A MOLECULAR WEIGHT OF
1518 DALTONS
SERIAL NUMBER : 09/845,765
FILING DATE : 04/30/01
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1616
ATTORNEY DOCKET NO. : 2132.036

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 12/9/02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.


Date:

12/9/2002

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



RECEIVED
DEC 17 2002
TECH CENTER 1600/2900

Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2132.036

APPLICATION NO.
09/845,765

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
JACKOWSKI et al.

FILING DATE
04/30/01

GROUP
1616

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5,827,659	10/98	Patterson				
		5,817,768	10/98	Griener et al.				
		5,538,897	07/96	Yates, III et al.				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 96/14580	05/96	PCT			X	
		WO 00/09562	02/00	PCT			X	
		WO 01/05422	01/01	PCT				X
		WO 00/49410	08/00	PCT			X	
		WO 01/75454	10/01	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Sobel, et al., "Antipeptide Monoclonal Antibodies to Defined Fibrinogen A α Chain Regions: Anti-A α 487-498, a Structural Probe for Fibrinogenolysis", Blood (1998), Vol. 91, No. 5, pp. 1590-1598.
		Scharfstein, et al., "Usefulness of Fibrinolytic and Procoagulant Markers During Thrombolytic Therapy in Predicting Clinical Outcomes in Acute Myocardial Infarction", Am. Journal of Cardiology (1996), Vol. 78, No. 5, pp. 503-510.
		Database Entrez-Protein Online!, "Fibrinogen Alpha", National Center for Biotechnology Information (NCBI), June 15 (2000), Disclosed FPA sequence: aa 20-35, retrieved from www.ncbi.nlm.nih.gov.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.